Modern approaches to obesity therapy: efficiency problems


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The high prevalence of obesity in almost all developed countries is one of the most significant medical problems of modern society. Despite the fact that the main factors leading to the development of obesity are well known, the search for effective treatments remains a major challenge. The article discusses the methods of treatment of obesity, the most commonly used at the present time. The treatment of obesity is based on an integrated approach that includes non-drug methods and diet therapy and an active lifestyle, as well as drug therapy. It is emphasized that any of these methods should be used for a sufficiently long period of time to achieve the result and involves the active participation of the patient. Sometimes the patient’s expectations of achieving a quick result are not justified, this leads him to disappointment, and in some cases to refusal of treatment. The authors analyze individual factors that affect both patient compliance and the effectiveness of ongoing obesity therapy. The article discusses the reasons for the low effectiveness of the recommended methods in some cases, as well as indications and limitations for the use of groups of drugs approved by clinical guidelines.

Full Text

Restricted Access

About the authors

Irina A. Kurnikova

Peoples' Friendship University of Russia

Email: curnikova@yandex.ru
Dr. Sci. (Med.), Professor, Professor at the Department of Hospital Therapy with Courses of Endocrinology, Hematology and Clinical Laboratory Diagnostics, Medical Institute, Curator of the Course of Endocrinology

Sh. G Gulova

Peoples' Friendship University of Russia

S. A Buturlina

Peoples' Friendship University of Russia

I. Mokhammed

Peoples' Friendship University of Russia

References

  1. Arroyo-Johnson C., Mincey K.D. Obesity Epidemiology Worldwide. Gastroenterol Clin North Am. 2016;45(4):571-79. Doi: 10.1016/j. gtc.2016.07.012.
  2. Bastard J., Maachi M., Lagathu C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4-12.
  3. Клиническая рекомендация по ожирению 2020. URL: https://rae-org.ru/system/files/ documents/pdf/ozhirenie_vzroslye.pdf
  4. Farooq M.A., Parkinson K.N., Adamson A.J., et al. Timing of the U/cIp/ in physical activity in childhood andoUol1oc1PC1: Gateshead Millennium Cohort Study. Br J. Sports Med. 2018;52:1002-6. doi: 10.1136/bjoporto-2016-096933.
  5. Lenz M., Richter T., Muhlhauser I. The morbidity and mortality associated with overweight and obesity in adulthood: a systematic review. Dtsch Arztebl Int. 2009;106:641-48. Doi: 10.3238/ arztebl.2009.0641
  6. Heymofield S.B., Waddep T.A. Mechanisms, Pathophysiology, and Management of Obesity. N. Engl J. Med. 2017;376(3):254-66. doi: 10.1056/NEJMra1514009.
  7. Yeo G., Heisler L. Unraveling the brain regulation of appetite: lessons from genetics. Nat Neurosci. 2012;15(10):1343-49. doi: 10.1038/pp.3211.
  8. Zhi C., Huang J., Wang J., et al. Connection between gut microbiome and the U1V1lopm1Pt of obesity. Eur J. Clin Microbiol Infect Dis. 2019;Jul 31. doi: 10.1007/s10096-019-03623-x.
  9. Fromentin C., Tomé D., Nau F., et al. Dietary proteins contribute little to glucose production, even under optimal gluconeogenic conditions in healthy humans. Diabetes. 2013;62(5):1435-42. doi: 10.2337/db12-1208.
  10. Veldhuis J.D., Sharma A., Roelfsema F., et al. Age-dependent and gender-dependent regulation of hypothalamic-adrenocorticotropic-adrenal axis Endocrinol Metab Clin North Am. 2013;42(2):201-25. Doi: 10.1016/j. ecl.2013.02.002
  11. Бобров А.Е., Гегель Н.А., Гурова О.Ю. Особенности поведения больных с избыточной массой тела и ожирением. Альманах клинической медицины. 2014;32:3-7.
  12. Зайцев В.П., Зайцев В.П. Психологическая реабилитация больных. Медицинская реабилитация. Под ред. В.М. Боголюбова. М.: БИНОМ, 2010. Т. 1. С. 325-47.
  13. Дадаева В.А., Еганян РА., Королев А.И. и др. Типы нарушений пищевого поведения. Профилактическая медицина. 2021;24(4): 113-19. Doi: 10.17116/ profm1U202124041113.
  14. Geliebter A., Christopher N., Ochner C.N., et al. Obesity-related hormones and metabolic risk factors: a randomized trial of diet plus either strength or aerobic training versus diet alone in overweight participants. J Diabetes Obes. 2015;1:1-7.
  15. Stephens S.K., Cobiac L.J., Leppert Veermap. J. Improving diet and physical activity to reduce population prevalence of overweight and obesity: An overview of current evidence. Preventive Medicine. 2014;62:167-78. Doi: 10.1016/j. ypm1d.2014.02.008.
  16. Heymsfield S.B., Waddep T.A. Mechanisms, Pathophysiology, and Management of Obesity. N. Engl J. Med. 2017;376(3):254-66. doi: 10.1056/NEJMm1514009.
  17. Guh D., Zhang W., Bansback N., et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and metaanalysis. BMC Public Health. 2009;9:88. doi: 10.1186/1471-2458-9-88.
  18. Jensen M.D., Ryan D.H., Apovian C.M., et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Society. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: a report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(suppl 2):S102-S138. doi: 10.1161/01.cir.0000437739.71477.ee
  19. Garvey WT, Mechanick J.I., Brett E.M., et al.; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22(Suppl 3):1-203. doi: 10.4158/EP161365.GL.
  20. Wirth A. Reduction of body weight and comorbidities by rollstart: The XXL primary Health Care Trial. Diabetes Obes. Metabol. 2005;7:2122. doi: 10.1111/j.1463-1326.2004.00428.x.
  21. Toplak H., Ziegler O., Keller U., Hamann A., et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet. Early response to treatment predicts weight maintenance. Diabetes Obes Metab. 2005;7:699-708. doi: 10.1111/j.1463-1326.2005.00483.x.
  22. Torgerson J.S., Hauptman J., Boldrin M.N., et al. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-61. doi: 10.2337/ diacare.27.1.155.
  23. Zheng J., Greenway F.L. Caenorhabditis elegans as a model for obesity research. Int J. Obes (Lond). 2012;36(2):186-94. doi: 10.1038/ ijo.2011.93.
  24. Neary M.T., Batterham R.L. Gut hormones: implications for the treatment of obesity Pharmacol Ther. 2009;124(1):44-56. doi: 10.1016/j.pharmthera.2009.06.005.
  25. Culbert K., Racine S., Klump K. Research Review: What we have learned about the causes of eating disorders - a synthesis of sociocultural, psychological, and biological research. J. Child Psychol Psychiatry. 2015;56(11):114164. doi: 10.1111/jcpp.12441.
  26. Peeters A.V., Beckers S., Verrijken A. Common variants in the gene for the serotonin receptor 6 (HTR6) do not contribute to obesity. J. Genet. 2010;89(4):469-72. doi: 10.1007/s12041-010-0066-2.
  27. Власова И.И., Аметов А.С. Влияние терапии Сибутрамином (Меридиа) на композиционный состав тела, уровни пептида YY3-36 и серотонина у пациентов с экзо- генно-конституциональным ожирением. Терапевтический архив. 2010;82(8):44-7.
  28. Caterson I.D., Finer N., Coutinho W., et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab. 2012;14(6): 523-30. doi: 10.1111/j.1463-1326. 2011.01554.x.
  29. Аметов А.С. Эффективное лечение ожирения-путь борьбы с эпидемией Diabetus mellipidus. Медицинский совет. 2013;2:78-83. doi: 10.21518/2079-701X-2013-2-2-78-83.
  30. Дедов И.И., Мельниченко ГА., Романцова Т.И. Стратегия управления ожирением: итоги Всероссийской наблюдательной программы «ПримаВера». Ожирение и метаболизм. 2016;1:36-44.
  31. Dedov I.I., еt al. Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. Obes Facts. 2018;11:335-43. doi: 10.1159/000488880.
  32. Campbell J.E., Drucker D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-37. doi: 10.1016/j.cmet.2013.04.008.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies